Chonsat 100 mg/ml solution for intramuscular injection

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of peripheral joints;

• intervertebral osteochondrosis and osteoarthritis. To accelerate the formation of callus in fractures.

Section: Method of administration and doses

The drug is administered intramuscularly at 1 ml (100 mg) every other day. With good tolerance, the dose is increased to 2 ml (200 mg), starting from the fourth injection. The treatment course is 25-30 injections.

If necessary, repeated courses may be conducted after 6 months. To form a bone callus, the treatment course lasts 3-4 weeks (10-14 injections every other day).

Composition per 1 ml:
Active ingredient: sodium chondroitin sulfate (calculated as dry substance) - 100 mg;
Excipients: water for injections - up to 1.0 ml.

Description of the dosage form

Transparent colorless solution or a solution with a slight yellowish tint.

• Increased sensitivity to the drug or its components.

• Bleeding and tendency to bleed, thrombophlebitis.

• Childhood age.

• Pregnancy and lactation period (data on the safety of the drug's use are currently lacking).

Special instructions

Use in pediatrics
Data on the efficacy and safety of chondroitin sulfate in children is currently unavailable.

Side effects

Possible allergic reactions (skin itching, erythema, urticaria, dermatitis), hemorrhages at the injection site. In these cases, the drug is discontinued.

Overdose

Currently, there have been no reported cases of chondroitin sulfate overdose.

Interaction

When undergoing treatment with the drug Khonsat®, caution should be exercised with the simultaneous use of direct-acting anticoagulants.
There may also be an enhancement of the effects of indirect anticoagulants, antiplatelet agents, and fibrinolytics, which requires more frequent monitoring of blood coagulation parameters during concurrent use.

Section: Pharmacodynamics

High molecular weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. The drug has chondroprotective properties, stimulates the regeneration of cartilage tissue, and has anti-inflammatory effects. It participates in the construction of the fundamental substance of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and functions of articular cartilage, and slows down the processes of cartilage tissue degeneration. It stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, and promotes the regeneration of cartilage surfaces and the joint capsule. It prevents the compression of connective tissue, increases the production of synovial fluid and the mobility of affected joints, reduces accompanying inflammation and pain, and helps to decrease the need for NSAIDs. In cases of degenerative changes in cartilage tissue, it serves as a means of replacement therapy. A positive effect is observed within 2-3 weeks after the start of the drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, and the range of motion in affected joints increases. The therapeutic effect lasts for a long time (3-6 months) after the end of the treatment course.

Pharmacokinetics

Chondroitin sulfate is easily absorbed after intramuscular administration. Already 30 minutes after the injection, it is found in the blood in significant concentrations. The maximum concentration (Cmax) of chondroitin sulfate in plasma is reached after 1 hour, then gradually decreases over 2 days.
Chondroitin sulfate accumulates mainly in the cartilage tissue of the joints. The synovial membrane does not pose a barrier to the penetration of the drug into the joint cavity. Fifteen minutes after the intramuscular injection, chondroitin sulfate is found in the synovial fluid, then it penetrates into the articular cartilage, where its content reaches a maximum after 48 hours.

Store in a protected from light place, at a temperature not exceeding 25°C. Do not freeze.